EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report

Jianbin Zhang, Sishi Huang, Hui Shen

Frontiers in Oncology · 08.05.2026 · 16

DOI: 10.3389/fonc.2026.1699804 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 08.05.2026. Verfasst von Jianbin Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib is the standard adjuvant therapy for resected epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). However, its use is limited by osimertinib-induced interstitial lung disease (Osi-ILD). Case Presentation We describe the case of a 62-year-old woman with resected stage IIB (pT1cN1M0) EGFR L858R-mutant lung adenocarcinoma who developed grade 2 Osi-ILD, characterized by new bilateral ground-glass opacities on high-resolution computed tomography (HRCT), after 3 months of adjuvant osimertinib therapy. Osimertinib was immediately discontinued, leading to complete symptomatic and radiographic resolution within 8 weeks without corticosteroid therapy. Given the high risk of ILD recurrence upon rechallenge and the suboptimal efficacy of chemotherapy, a multidisciplinary team consensus recommended switching to almonertinib (110 mg once daily). Remarkably, the patient has maintained disease-free survival without ILD relapse for 36 months.

Conclusion

This case provides clinical evidence that switching to almonertinib may represent a viable and safe therapeutic strategy, thereby addressing a critical unmet need in the management of resected early-stage EGFR-mutant NSCLC after Osi-ILD.

Schlagwörter

Stichwörter der Autor:innen

EGFR-TKIadjuvant therapyalmonertinibcase reportinterstitial lung diseasenon-small cell lung cancerosimertinib

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
  • Department of Respiratory Medicine, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.

Zitieren

APA

Zhang, J., Huang, S., & Shen, H. (2026). Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1699804

Vancouver

Zhang J, Huang S, Shen H. Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1699804

BibTeX
@article{Zhang2026,
  author = {Zhang, Jianbin and Huang, Sishi and Shen, Hui},
  title = {Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1699804}
}
Kostenlos starten →